Brightsurf Science News & Current Events

December 06, 2003
Three months is too soon to judge a CML patient's response to Gleevec, researchers find
Gleevec has been shown to wipe out leukemia cells in 75 percent of the chronic myeloid leukemia (CML) patients who are treated with it.

New advances in thrombosis help further understanding of disease prevention
Several studies presented during the 45th Annual Meeting of the American Society of Hematology shed light on some promising new therapies that are in the pipeline for the treatment of thrombosis, as well as some potential risk factors, and may provide hope for the numerous patients suffering from this condition.

Novel therapies show promise against myeloid leukemia
Leukemia, a cancer of the white blood cells, starts in the bone marrow but can spread to the blood, lymph nodes, and other organs.
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.